AAPL   317.01 (-0.59%)
MSFT   181.62 (-1.03%)
GOOGL   1,425.79 (+1.24%)
AMZN   2,418.89 (-0.74%)
NVDA   349.45 (-3.22%)
BABA   202.40 (+1.56%)
GE   6.87 (+7.18%)
TSLA   820.38 (+0.43%)
AMD   53.82 (-2.45%)
T   31.07 (+3.98%)
F   5.88 (+3.89%)
GILD   73.71 (+0.50%)
DIS   122.11 (+3.47%)
BAC   24.59 (+8.52%)
BA   145.61 (+5.88%)
AAPL   317.01 (-0.59%)
MSFT   181.62 (-1.03%)
GOOGL   1,425.79 (+1.24%)
AMZN   2,418.89 (-0.74%)
NVDA   349.45 (-3.22%)
BABA   202.40 (+1.56%)
GE   6.87 (+7.18%)
TSLA   820.38 (+0.43%)
AMD   53.82 (-2.45%)
T   31.07 (+3.98%)
F   5.88 (+3.89%)
GILD   73.71 (+0.50%)
DIS   122.11 (+3.47%)
BAC   24.59 (+8.52%)
BA   145.61 (+5.88%)
AAPL   317.01 (-0.59%)
MSFT   181.62 (-1.03%)
GOOGL   1,425.79 (+1.24%)
AMZN   2,418.89 (-0.74%)
NVDA   349.45 (-3.22%)
BABA   202.40 (+1.56%)
GE   6.87 (+7.18%)
TSLA   820.38 (+0.43%)
AMD   53.82 (-2.45%)
T   31.07 (+3.98%)
F   5.88 (+3.89%)
GILD   73.71 (+0.50%)
DIS   122.11 (+3.47%)
BAC   24.59 (+8.52%)
BA   145.61 (+5.88%)
AAPL   317.01 (-0.59%)
MSFT   181.62 (-1.03%)
GOOGL   1,425.79 (+1.24%)
AMZN   2,418.89 (-0.74%)
NVDA   349.45 (-3.22%)
BABA   202.40 (+1.56%)
GE   6.87 (+7.18%)
TSLA   820.38 (+0.43%)
AMD   53.82 (-2.45%)
T   31.07 (+3.98%)
F   5.88 (+3.89%)
GILD   73.71 (+0.50%)
DIS   122.11 (+3.47%)
BAC   24.59 (+8.52%)
BA   145.61 (+5.88%)
Log in

NASDAQ:CASICASI Pharmaceuticals Stock Price, Forecast & News

$2.71
+0.02 (+0.74 %)
(As of 05/26/2020 03:41 PM ET)
Add
Compare
Today's Range
$2.59
Now: $2.71
$2.78
50-Day Range
$1.66
MA: $1.89
$2.69
52-Week Range
$1.15
Now: $2.71
$3.82
Volume329,673 shs
Average Volume278,008 shs
Market Capitalization$273.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.81
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Read More
CASI Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 million
Book Value$0.76 per share

Profitability

Net Income$-46,030,000.00

Miscellaneous

Employees124
Market Cap$273.49 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

How has CASI Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CASI shares have increased by 66.3% and is now trading at $2.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CASI Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CASI Pharmaceuticals.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for CASI Pharmaceuticals.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals Inc (NASDAQ:CASI) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The biotechnology company had revenue of $3.41 million for the quarter, compared to analyst estimates of $0.79 million. View CASI Pharmaceuticals' earnings history.

What price target have analysts set for CASI?

1 brokerages have issued 1 year target prices for CASI Pharmaceuticals' stock. Their forecasts range from $3.50 to $3.50. On average, they expect CASI Pharmaceuticals' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. View analysts' price targets for CASI Pharmaceuticals.

Has CASI Pharmaceuticals been receiving favorable news coverage?

Headlines about CASI stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCASI Pharmaceuticals.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,310,000 shares, a decrease of 5.3% from the April 30th total of 2,440,000 shares. Based on an average trading volume of 231,000 shares, the short-interest ratio is presently 10.0 days. Currently, 5.3% of the shares of the stock are short sold. View CASI Pharmaceuticals' Current Options Chain.

Who are some of CASI Pharmaceuticals' key competitors?

What other stocks do shareholders of CASI Pharmaceuticals own?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:
  • Dr. Wei-Wu He, Chairman & CEO (Age 54)
  • Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
  • Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
  • Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.22%), Ikarian Capital LLC (1.03%), State Street Corp (0.90%), Geode Capital Management LLC (0.70%), Bank of New York Mellon Corp (0.17%) and Vident Investment Advisory LLC (0.08%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman and Wei-Wu He. View institutional ownership trends for CASI Pharmaceuticals.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, BlackRock Inc., and IHT Wealth Management LLC. View insider buying and selling activity for CASI Pharmaceuticals.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, WINTON GROUP Ltd, Geode Capital Management LLC, SG Americas Securities LLC, Vident Investment Advisory LLC, Wellesley Investment Partners LLC, Alliancebernstein L.P., and JPMorgan Chase & Co.. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, and Wei-Wu He. View insider buying and selling activity for CASI Pharmaceuticals.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.71.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $273.49 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.